Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07TGN
|
|||
| Former ID |
DAP000464
|
|||
| Drug Name |
Deslanoside
|
|||
| Synonyms |
Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arrhythmia [ICD-11: BC9Z] | Approved | [1], [2], [3] | |
| Congestive cardiac insufficiency [ICD-11: BD1Z; ICD-10: I50, I50.9] | Approved | [1], [2], [3] | ||
| Heart failure [ICD-11: BD10-BD13] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C47H74O19
|
|||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)O)O
|
|||
| InChI |
1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
|
|||
| InChIKey |
OBATZBGFDSVCJD-LALPQLPRSA-N
|
|||
| CAS Number |
CAS 17598-65-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:31468
|
|||
| SuperDrug ATC ID |
C01AA07
|
|||
| SuperDrug CAS ID |
cas=017598651
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6806). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009282. | |||
| REF 4 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.